Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2022

Supporting Information

Stereoselective Synthesis of C3-Tetrasubstituted oxindoles via

Copper Catalyzed Asymmetric Propargylation

Jiao-Mei Wang,^{a,1} Yu Zhao,^{b,1} Chang-Sheng Yao,^{*,c} and Kai Zhang^{*,c}

^a School of Materials and Chemical Engineering, Xuzhou University of Technology, Xuzhou 221018, P R China

^b College of Chemistry and Chemical Engineering, Yan'an University, Yan'an, Shaanxi 716000, P R China

^c Jiangsu Key Lab of Green Synthetic Chemistry for Functional Materials, School of Chemistry and Materials Science, Jiangsu Normal University, Xuzhou, Jiangsu 221116, P R China

¹ Jiaomei Wang and Yu Zhao contributed equally to this work.

E-mail: zhangkai@jsnu.edu.cn.

Table of Contents

1.	General InformationS2
2.	Preparation of the MaterialsS2
3.	General Procedures of products
4.	Characterization Data of the ProductsS4
5.	X-Ray Structures of Product (S,R)-3i and (R,S)-3mS11
6.	Copies of ¹ H and ¹³ C NMR SpectraS13
7.	Copies of HPLC Chromatograpgy

1. General Information

Unless otherwise noted, materials were purchased from commercial suppliers and used without further purification. All the solvents were treated according to standard methods. Flash column chromatography was performed using 200-300 mesh silica gel. ¹H NMR spectra were recorded on 400 MHz spectrophotometers. Chemical shifts (δ) are reported in ppm from the resonance of tetramethyl silane as the internal standard (TMS: 0.00 ppm). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet), coupling constants (Hz) and integration. ¹³C NMR spectra were recorded on 100 MHz with complete proton decoupling spectrophotometers (CDCl₃: 77.0 ppm). Enantiomeric excesses (ee) were determined by HPLC analysis on ThermoFisher UltiMate 3000 chiral HPLC with chiral AD-H, IC-H, OJ-H columns with hexane and *i*PrOH as solvents. The high resolution mass spectra (HRMS) were measured on a Shimadzu LCMS-IT-TOF mass spectrometer or DIONEX UltiMate 3000 & Bruker Compact TOF mass spectrometer by ESI.

2. Preparation of the Substrates

All the solvents were treated according to standard methods and all chemicals were used without purification. The 2-oxindole-3-carboxylate esters 1^1 and terminal propargylic esters 2^2 were known compounds or prepared from conventional methods.





3. General Procedures of the Products

3.1 General procedure for the synthesis of products 3.



Procedure: An oven-dried 10 mL Schlenk tube equipped with a magnetic stir bar was charged with CuI (0.02 mmol, 10 mol%), chiral PyBOX ligand **L6** (0.024 mmol, 12 mol%) and MeOH (3 mL). The resulting solution was stirred for 1 h at room temperature. Then 2-oxindole-3-carboxylate esters **1** (0.2 mmol, 1.0 eq) and *i*Pr₂NEt (0.44 mmol, 2.2 eq) were added stirring for 5 min at room temperature before cooled to -15 °C. Then the propargylic acetate **2** (0.3 mmol, 1.5 eq) were introduced at -15 °C. The resulting solution was stirred until complete convertion of substrate **1** as monitored by TLC analysis. The resulting mixture was evaporated and purified by flash column chromatography on silica gel (PE/EA=20/1-10/1) to give product **3**. All the products **3** were prepared according to the above procedure.

3.2 General procedure for the Click reaction of (S,R)-3f.



Procedure: Under argon atmosphere, a flame-dried 10 ml Schlenk tube was charged with

compound (*S*,*R*)-**3f** (0.1 mmol, 1.0 eq), zidovudine (0.11 mmol, 1.1 eq), tBuOH (1.0 mL) and a stir bar was added a freshly prepared solution of CuSO₄ (0.05 mmol, 0.5 eq) and sodium ascorbate (0.05 mmol, 0.5 eq) in H₂O (1.0 mL). The resulting solution was stirred at room temperature for 20 h. The resulting mixture was concentrated and subjected to column chromatography (DCM/MeOH = 20/1) to give product **4** as an white solid.

4. Characterization Data of Products

Ethyl (R)-1-methyl-2-oxo-3-((R)-1-phenylprop-2-yn-1-yl)indoline-3-carboxylate ((R,R)-3a)



White solid, 36% yield; $[\alpha]_D^{23} = 1.532$ (c = 1.00 in CH₂Cl₂); 91% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 4.84 min, t_R (minor) = 5.90 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.84 (d, J = 7.5 Hz, 1H), 7.37 – 7.23 (m, 1H), 7.21

- 6.82 (m, 6H), 6.52 (d, J = 7.8 Hz, 1H), 5.05 – 4.79 (m, 1H), 4.29 (q, J = 7.1 Hz, 2H), 2.77 (s, 3H), 2.45 (d, J = 1.4 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 170.81, 167.21, 143.93, 133.99, 129.29, 128.92, 127.68, 127.39, 125.99, 125.27, 122.46, 107.83, 82.40, 73.20, 63.50, 62.36, 42.81, 26.05, 14.04; HRMS (ESI) for: C₂₁H₂₀NO₃ [M+H]⁺: calcd 334.1438, found 334.1447.

Ethyl (S)-1-methyl-2-oxo-3-((R)-1-phenylprop-2-yn-1-yl)indoline-3-carboxylate ((S,R)-3a)



White solid, 56% yield; $[\alpha]_D^{23} = 1.735$ (c = 1.00 in CH₂Cl₂); 95% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 8.90 min, t_R (minor) = 17.52 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.28 – 7.00 (m, 9H), 6.62 (d, J = 7.8 Hz, 1H), 4.84 (d, J = 2.6 Hz, 1H), 4.29 – 4.18 (m, 2H), 3.01 (s, 3H), 2.32 (d, J =

2.5 Hz, 1H), 1.23 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 171.10, 167.55, 144.13, 134.23, 129.38, 129.32, 127.84, 127.61, 125.19, 125.03, 122.09, 107.91, 80.73, 73.13, 63.25, 62.29, 43.13, 26.17, 13.95; **HRMS** (ESI) for: C₂₁H₂₀NO₃ [M+H]⁺: calcd 334.1438, found 334.1447.

Ethyl (R)-5-bromo-1-methyl-2-oxo-3-((R)-1-phenylprop-2-yn-1-yl)indoline-3-carboxylate ((*R*,*R*)-3b)



White solid, 42% yield, $[\alpha]_D^{23} = -3.473$ (c = 1.00 in CH₂Cl₂); 90% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 5.29 min, t_R (minor) = 6.28 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 8.04 – 7.90 (m, 1H), 7.42 – 7.39 (m, 1H), 7.18 – 6.91 (m, 5H), 6.39 (d, J = 8.3 Hz, 1H), 4.89 (d,

J = 2.5 Hz, 1H), 4.30 (q, *J* = 7.1 Hz, 2H), 2.75 (s, 3H), 2.50 (d, *J* = 2.1 Hz, 1H), 1.29

(t, J = 7.1 Hz, 3H); ¹³**C** NMR (100 MHz, CDCl₃): δ (ppm) 170.22, 166.49, 142.96, 133.56, 132.13, 129.07, 128.84, 127.87, 127.56, 127.14, 115.04, 109.20, 81.79, 73.77, 63.47, 62.63, 42.85, 26.13, 14.00; **HRMS** (ESI) for: C₂₁H₁₉BrNO₃ [M+H]⁺: calcd 412.0543, found 412.0544.

Ethyl (S)-5-bromo-1-methyl-2-oxo-3-((R)-1-phenylprop-2-yn-1-yl)indoline-3-carboxylate ((*S*,*R*)-3b)



White solid, 51% yield, $[\alpha]_D^{23} = 1.390$ (c = 1.00 in CH₂Cl₂); 88% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) =31.05 min, t_R (minor) = 37.83 min; ¹H **NMR** (400 MHz, CDCl₃): δ (ppm) 7.41 – 7.38 (m, 1H), 7.24 –

7.23 – 7.18 (m, 5H), 7.08 (t, J = 1.5 Hz, 1H), 6.54 (d, J = 8.3 Hz, 1H), 4.85 (d, J = 2.5 Hz, 1H), 4.24 (q, J = 7.1 Hz, 2H), 3.02 (s, 3H), 2.30 (d, J = 1.2 Hz, 1H), 1.24 (t, J = 7.1 Hz, 3H); ¹³**C NMR** (100 MHz, CDCl₃): δ (ppm) 170.58, 166.81, 143.24, 133.87, 132.18, 129.31, 128.64, 128.18, 127.84, 126.80, 114.58, 109.30, 80.23, 73.40, 63.32, 62.60, 43.23, 26.33, 13.96; **HRMS** (ESI) for: C₂₁H₁₉BrNO₃ [M+H]⁺: calcd 412.0543, found 412.0544.

Ethyl (R)-5-chloro-1-methyl-2-oxo-3-((R)-1-phenylprop-2-yn-1-yl)indoline-3-carboxylate ((*R*,*R*)-3c)



White solid, 44% yield, $[\alpha]_D^{23} = 0.898$ (c = 1.00 in CH₂Cl₂); 90% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 5.20 min, t_R (minor) = 6.38 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.83 (t, J = 1.6 Hz, 1H), 7.30 – 7.22 (m, 1H), 7.14 – 6.91 (m, 5H), 6.45 – 6.42 (m, 1H), 4.91 –

4.88 (m, 1H), 4.30 (q, J = 7.1 Hz, 2H), 2.76 (s, 3H), 2.50 (d, J = 1.5 Hz, 1H), 1.29 (t, J = 7.1 Hz, 3H); ¹³**C NMR** (100 MHz, CDCl₃): δ (ppm) 170.31, 166.49, 142.47, 133.55, 129.23, 128.83, 127.86, 127.77, 127.55, 126.79, 126.36, 108.70, 81.80, 73.75, 63.56, 62.62, 42.83, 26.16, 14.00; **HRMS** (ESI) for: C₂₁H₁₉ClNO₃ [M+H]⁺: calcd 368.1048, found 368.1057.

Ethyl (S)-5-chloro-1-methyl-2-oxo-3-((R)-1-phenylprop-2-yn-1-yl)indoline-3-carboxylate ((*S*,*R*)-3c)



White solid, 53% yield, $[\alpha]_D^{23} = 0.879$ (c = 1.00 in CH₂Cl₂); 87% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) =28.99 min, t_R (minor) = 46.50 min; ¹H **NMR** (400 MHz, CDCl₃): δ (ppm) 7.28 – 7.15 (m, 6H), 6.96 (t, J = 1.4 Hz, 1H), 6.58 (d, J = 8.3 Hz, 1H), 4.85 (d, J = 2.6 Hz,

1H), 4.27 – 4.21 (m, 2H), 3.03 (s, 3H), 2.30 (d, J = 2.5 Hz, 1H), 1.24 (t, J = 7.1 Hz, 3H); ¹³**C NMR** (100 MHz, CDCl₃): δ (ppm) 170.80, 166.94, 142.89, 134.02, 129.44, 128.29, 127.97, 127.54, 126.59, 126.03, 108.92, 80.37, 73.52, 63.51, 62.71, 43.35,

26.48, 14.08; **HRMS** (ESI) for: $C_{21}H_{18}CINO_3Na [M+Na]^+$: calcd 390.0867, found 390.0875.

Ethyl (R)-1,5-dimethyl-2-oxo-3-((R)-1-phenylprop-2-yn-1-yl)indoline-3-carboxylate ((*R*,*R*)-3d)



White solid, 34% yield, $[\alpha]_D^{23} = 0.334$ (c = 1.00 in CH₂Cl₂); 90% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 4.74 min, t_R (minor) = 5.53 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.65 (s, 1H), 7.14 – 6.88 (m, 5H), 6.41 (d, J = 7.9 Hz, 1H), 4.94 – 4.83 (m, 1H), 4.33 – 4.24 (m, 2H),

2.75 (s, 3H), 2.44 (d, J = 3.6 Hz, 1H), 2.42 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 170.77, 167.39, 141.59, 134.12, 131.95, 129.60, 128.97, 127.63, 127.39, 126.65, 125.22, 107.54, 82.50, 73.07, 63.51, 62.34, 42.73, 26.07, 21.35, 14.04; **HRMS** (ESI) for: C₂₂H₂₂NO₃ [M+H]⁺: calcd 348.1594, found 348.1604.

Ethyl (S)-1,5-dimethyl-2-oxo-3-((R)-1-phenylprop-2-yn-1-yl)indoline-3-carboxylate ((*S*,*R*)-3d)



White solid, 50% yield, $[\alpha]_D^{23} = 1.600$ (c = 1.00 in CH₂Cl₂); 95% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 11.53 min, t_R (minor) = 14.99 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.22 – 7.08 (m, 5H), 7.05 (d, J = 7.9 Hz, 1H), 6.87 (s, 1H), 6.50 (d, J = 7.9 Hz, 1H), 4.82 (d, J = 2.4

Hz, 1H), 4.24 (q, J = 7.1 Hz, 2H), 2.98 (s, 3H), 2.31 (d, J = 3.9 Hz, 3H), 1.24 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 171.05, 167.74, 141.75, 134.29, 131.58, 129.60, 129.33, 127.77, 127.51, 125.85, 124.97, 107.59, 80.87, 73.02, 63.28, 62.23, 43.02, 26.15, 21.08, 13.95; **HRMS** (ESI) for: C₂₂H₂₁NO₃Na [M+Na]⁺: calcd 370.1414, found 370.1419.

Ethyl (R)-5-methoxy-1-methyl-2-oxo-3-((R)-1-phenylprop-2-yn-1-yl)indoline-3-carboxylate ((*R*,*R*)-3e)



White solid, 38% yield, $[\alpha]_D^{23} = 1.007$ (c = 1.00 in CH₂Cl₂); 92% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 5.73 min, t_R (minor) = 7.67 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.48 (d, J = 2.6 Hz, 1H), 7.13 – 7.11 – 6.96 (m, 5H), 6.83 – 6.80 (m, 1H), 6.43 – 6.41 (m, 1H),

4.89 (d, J = 2.7 Hz, 1H), 4.29 (q, J = 7.2 Hz, 2H), 3.86 (s, 3H), 2.74 (s, 3H), 2.46 (d, J = 1.5 Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H); ¹³**C** NMR (100 MHz, CDCl₃): δ (ppm) 170.47, 167.14, 155.60, 137.55, 133.98, 128.92, 128.68, 127.66, 127.55, 127.41, 127.29, 126.42, 113.64, 113.30, 108.08, 82.40, 73.24, 63.74, 62.35, 55.83, 42.69, 26.12, 14.03; **HRMS** (ESI) for: C₂₂H₂₂NO₄ [M+H]⁺: calcd 364.1543, found 364.1544.

Ethyl (S)-5-methoxy-1-methyl-2-oxo-3-((R)-1-phenylprop-2-yn-1-yl)indoline-3-carboxylate ((S,R)-3e)



White solid, 49% yield, $[\alpha]_D^{23} = -3.965$ (c = 1.00 in CH₂Cl₂); 94% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 15.61 min, t_R (minor) = 33.97 min; ¹H **NMR** (400 MHz, CDCl₃): δ (ppm) 7.19 (m, 5H), 6.81 – 6.78 (m, 1H), 6.62 (d, J = 2.5 Hz, 1H), 6.55 (d, J = 8.5 Hz, 1H),

4.85 (d, J = 2.5 Hz, 1H), 4.27 – 4.19 (m, 2H), 3.73 (s, 3H), 3.01 (s, 3H), 2.29 (d, J = 2.3 Hz, 1H), 1.23 (t, J = 7.1 Hz, 3H); ¹³**C NMR** (100 MHz, CDCl₃): δ (ppm) 170.82, 167.42, 155.33, 137.74, 134.29, 129.41, 127.90, 127.65, 126.03, 114.13, 112.39, 108.25, 80.67, 73.09, 63.63, 62.30, 55.75, 43.09, 26.29, 13.96; **HRMS** (ESI) for: C₂₂H₂₁NO₄Na [M+Na]⁺: calcd 386.1363, found 386.1361.

Ethyl (R)-6-bromo-1-methyl-2-oxo-3-((R)-1-phenylprop-2-yn-1-yl)indoline-3-carboxylate ((*R*,*R*)-3f)



White solid, 45% yield, $[\alpha]_D^{23} = 1.489$ (c = 1.00 in CH₂Cl₂); 91% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 5.24 min, t_R (minor) = 5.59 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.71 – 7.69 (m, 1H), 7.29 – 7.26 (m, 1H), 4.89 (d, J = 2.5 Hz, 1H), 4.28 (q, J = 7.1 Hz, 2H), 2.75

(s, 3H), 2.46 (d, J = 2.0 Hz, 1H), 1.28 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 170.60, 166.59, 145.19, 133.62, 128.85, 127.91, 127.61, 127.29, 125.34, 124.20, 123.07, 111.38, 82.05, 73.51, 63.32, 62.57, 42.70, 26.15, 14.01; **HRMS** (ESI) for: C₂₁H₁₉BrNO₃ [M+H]⁺: calcd 412.0543, found 412.0544.

Ethyl (S)-6-bromo-1-methyl-2-oxo-3-((R)-1-phenylprop-2-yn-1-yl)indoline-3-carboxylate ((*S*,*R*)-3f)



White solid, 50% yield, $[\alpha]_D^{23} = 0.739$ (c = 1.00 in CH₂Cl₂); 92% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 7.14 min, t_R (minor) = 14.16 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.24 – 7.10 (m, 6H), 6.85 – 6.76 (m, 2H), 4.86 (d, J = 2.5 Hz, 1H), 4.27 – 4.15 (m, 2H), 3.04 (s,

3H), 2.29 (d, J = 2.4 Hz, 1H), 1.21 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 170.97, 166.84, 145.50, 134.03, 129.35, 128.13, 127.86, 126.88, 124.91, 123.79, 123.15, 111.46, 80.30, 73.36, 63.16, 62.50, 43.02, 26.37, 13.93; **HRMS** (ESI) for: C₂₁H₁₉BrNO₃ [M+H]⁺: calcd 412.0543, found 412.0544.

Ethyl (R)-1-ethyl-2-oxo-3-((R)-1-phenylprop-2-yn-1-yl)indoline-3-carboxylate ((R,R)-3g)



White solid, 37% yield, $[\alpha]_D^{23} = 1.416$ (c = 1.00 in CH₂Cl₂); 67% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 4.89 min, t_R (minor) = 5.66 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.87 (d, J = 7.5 Hz, 1H), 7.33 – 7.25 (m, 1H), 7.18 – 7.05 (m, 2H), 7.01 (t, J = 7.5 Hz, 2H), 6.93 (d, J = 7.5 Hz, 2H),

6.57 (d, J = 7.8 Hz, 1H), 4.90 (d, J = 2.5 Hz, 1H), 4.27 (q, J = 7.1 Hz, 2H), 3.62 – 3.53 (m, 1H), 3.24 – 3.15 (m, 1H), 2.44 (d, J = 2.2 Hz, 1H), 1.25 (t, J = 7.1 Hz, 3H), 0.62 (t, J = 7.1 Hz, 3H); ¹³**C NMR** (100 MHz, CDCl₃): δ (ppm) 170.33, 167.35, 143.21, 134.26, 129.25, 129.23, 127.66, 127.56, 126.16, 125.57, 122.24, 108.05, 82.70, 73.04, 63.07, 62.29, 42.57, 34.55, 14.00, 11.52; **HRMS** (ESI) for: C₂₂H₂₂NO₃ [M+H]⁺: calcd 348.1594, found 348.1597.



White solid, 43% yield, $[\alpha]_D^{23} = 1.341$ (c = 1.00 in CH₂Cl₂); 94% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 6.38 min, t_R (minor) = 11.85 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.29 – 7.22 (m, 1H), 7.20 – 7.07 (m, 6H), 7.02 (t, *J* = 7.5 Hz, 1H), 6.65 (d, *J* = 7.8 Hz, 1H), 4.87 – 4.80 (m, 1H), 4.23 (q,

J = 7.1 Hz, 2H), 3.83 - 3.74 (m, 1H), 3.45 - 3.36 (m, 1H), 2.34 (d, J = 3.7 Hz, 1H), 1.23 (t, J = 7.1 Hz, 3H), 0.93 (t, J = 7.2 Hz, 3H); ¹³**C** NMR (100 MHz, CDCl₃): δ (ppm) 170.65, 167.71, 143.28, 134.17, 129.45, 129.35, 127.77, 127.67, 125.32, 125.25, 121.89, 108.10, 80.88, 73.23, 62.92, 62.24, 42.88, 34.58, 13.92, 11.81; **HRMS** (ESI) for: C₂₂H₂₁NO₃Na [M+Na]⁺: calcd 370.1414, found 370.1416.

Ethyl (R)-1-allyl-2-oxo-3-((R)-1-phenylprop-2-yn-1-yl)indoline-3-carboxylate ((R,R)-3h)



White solid, 43% yield, $[\alpha]_D^{23} = 1.993$ (c = 1.00 in CH₂Cl₂); 92% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 4.86 min, t_R (minor) = 5.55 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.89 (d, J = 7.4 Hz, 1H), 7.32 – 6.89 (m, 7H), 6.54 (d, J = 7.9 Hz, 1H), 5.22 – 5.06 (m, 1H), 4.99 – 4.82 (m, 2H), 4.57

(d, J = 17.5 Hz, 1H), 4.27 (q, J = 7.1 Hz, 2H), 4.18 – 4.07 (m, 1H), 3.85 – 3.78 (m, 1H), 2.45 (d, J = 3.8 Hz, 1H), 1.25 (t, J = 7.1 Hz, 3H); ¹³**C** NMR (100 MHz, CDCl₃): δ (ppm) 170.50, 167.25, 143.32, 134.30, 130.38, 129.27, 129.19, 127.70, 127.67, 125.96, 125.32, 122.41, 117.13, 108.97, 82.67, 73.07, 63.26, 62.35, 42.43, 42.23, 13.97; HRMS (ESI) for: C₂₃H₂₂NO₃ [M+H]⁺: calcd 360.1594, found 360.1596.

Ethyl (S)-1-allyl-2-oxo-3-((R)-1-phenylprop-2-yn-1-yl)indoline-3-carboxylate ((S,R)-3h)



White solid, 46% yield, $[\alpha]_D^{23} = 3.416$ (c = 1.00 in CH₂Cl₂); 91% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 6.35 min, t_R (minor) = 9.54 min; ¹H NMR (400 MHz,

CDCl₃): δ (ppm) 7.37 – 6.93 (m, 8H), 6.61 (d, J = 7.8 Hz, 1H), 5.45 (m, 1H), 5.01 (d, J = 10.3 Hz, 1H), 4.92 – 4.76 (m, 2H), 4.44 – 4.17 (m, 3H), 4.05 – 3.99 (m, 1H), 2.36 (d, J = 2.6 Hz, 1H), 1.23 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 170.77, 167.71, 143.35, 134.18, 130.70, 129.49, 129.32, 127.80, 127.74, 125.09, 124.95, 122.10, 117.33, 109.04, 80.98, 73.26, 63.13, 62.32, 42.74, 42.25, 13.92; **HRMS** (ESI) for: C₂₃H₂₁NO₃Na [M+Na]⁺: calcd 382.1414, found 382.1396.

Ethyl (R)-3-((R)-1-(4-bromophenyl)prop-2-yn-1-yl)-1-methyl-2-oxoindoline-3-carboxylate ((*R*,*R*)-3i)



White solid, 40% yield, $[\alpha]_D^{23} = 0.741$ (c = 1.00 in CH₂Cl₂); 91% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, λ = 254 nm, 25 °C), t_R (major) = 6.03 min, t_R (minor) = 7.03 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.81 (d, *J* = 7.5

Hz, 1H), 7.35 – 7.24 (m, 1H), 7.19 – 7.10 (m, 3H), 6.89 – 6.81 (m, 2H), 6.58 (d, J = 7.8 Hz, 1H), 4.91 – 4.83 (m, 1H), 4.27 (q, J = 7.1 Hz, 2H), 2.83 (s, 3H), 2.46 (d, J = 3.5 Hz, 1H), 1.26 (t, J = 7.1 Hz, 3H); ¹³**C NMR** (100 MHz, CDCl₃): δ (ppm) 170.66, 166.97, 143.86, 133.24, 130.68, 130.55, 129.50, 125.87, 124.93, 122.61, 121.88, 108.10, 81.85, 73.53, 63.22, 62.44, 42.10, 26.16, 13.98; **HRMS** (ESI) for: C₂₁H₁₉BrNO₃ [M+H]⁺: calcd 412.0543, found 412.0550.

Ethyl (S)-3-((R)-1-(4-bromophenyl)prop-2-yn-1-yl)-1-methyl-2-oxoindoline-3-carboxylate ((*S*,*R*)-3i)



White solid, 56% yield, $[\alpha]_D^{23} = 0.997$ (c = 1.00 in CH₂Cl₂); 96% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda =$ 254 nm, 25 °C), t_R (major) = 11.46 min, t_R (minor) = 12.54 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.34 – 7.22 (m, 3H), 7.09 – 7.01 (m, 4H), 6.67 (d, J = 7.8 Hz, 1H), 4.79 (d,

J = 2.4 Hz, 1H), 4.28 - 4.18 (m, 2H), 3.04 (s, 3H), 2.33 (d, J = 2.0 Hz, 1H), 1.22 (t, J = 7.1 Hz, 3H); ¹³**C** NMR (100 MHz, CDCl₃): δ (ppm) 170.95, 167.44, 144.13, 133.44, 131.12, 130.76, 129.63, 124.96, 124.77, 122.27, 122.07, 108.19, 80.27, 73.47, 63.01, 62.41, 42.42, 26.24, 13.95; **HRMS** (ESI) for: C₂₁H₁₉BrNO₃ [M+H]⁺: calcd 412.0543, found 412.0550.

Ethyl (R)-3-((R)-1-(3-bromophenyl)prop-2-yn-1-yl)-1-methyl-2-oxoindoline-3-carboxylate ((*R*,*R*)-3j)



White solid, 35% yield, $[\alpha]_D^{23} = 3.836$ (c = 1.00 in CH₂Cl₂); 87% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 5.11 min, t_R (minor) = 6.14 min; ¹H **NMR** (400 MHz, CDCl₃): δ (ppm) 7.81 (d, J = 7.5 Hz, 1H), 7.31 (t, J = 7.8 Hz, 1H), 7.25 – 7.12 (m, 2H), 7.05 (d, J = 1.8

Hz, 1H), 6.97 – 6.87 (m, 2H), 6.57 (d, J = 7.8 Hz, 1H), 4.85 (t, J = 2.0 Hz, 1H), 4.28

(q, J = 7.1 Hz, 2H), 2.83 (s, 3H), 2.47 (d, J = 2.1 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H); ¹³**C** NMR (100 MHz, CDCl₃): δ (ppm) 170.64, 166.93, 143.86, 136.37, 131.90, 130.80, 129.59, 128.86, 127.76, 125.89, 124.90, 122.67, 121.35, 108.01, 81.62, 73.76, 63.36, 62.47, 42.40, 26.14, 14.02; **HRMS** (ESI) for: C₂₁H₁₉BrNO₃ [M+H]⁺: calcd 412.0543, found 412.0552.

Ethyl (S)-3-((R)-1-(3-bromophenyl)prop-2-yn-1-yl)-1-methyl-2-oxoindoline-3-carboxylate ((S,R)-3j)



White solid, 46% yield, $[\alpha]_D^{23} = 2.632$ (c = 1.00 in CH₂Cl₂); 96% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 9.43 min, t_R (minor) = 14.96 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.37 – 7.22 (m, 3H), 7.15 – 7.12 (m, 1H), 7.08 – 6.96 (m, 3H), 6.67 (d, J = 7.8 Hz,

1H), 4.81 (d, J = 2.5 Hz, 1H), 4.29 – 4.18 (m, 2H), 3.05 (s, 3H), 2.33 (d, J = 3.7 Hz, 1H), 1.23 (t, J = 7.1 Hz, 3H); ¹³**C NMR** (100 MHz, CDCl₃): δ (ppm) 170.85, 167.30, 144.12, 136.63, 132.32, 130.96, 129.64, 129.10, 128.10, 125.10, 124.65, 122.24, 121.56, 108.11, 79.94, 73.66, 63.04, 62.42, 42.60, 26.22, 13.94; **HRMS** (ESI) for: C₂₁H₁₉BrNO₃ [M+H]⁺: calcd 412.0543, found 412.0552.

Ethyl (R)-3-((R)-1-(4-methoxyphenyl)prop-2-yn-1-yl)-1-methyl-2-oxoindoline-3-carboxylate ((R,R)-3k)



White solid, 41% yield, $[\alpha]_D^{23} = 0.881$ (c = 1.00 in CH₂Cl₂); 82% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda =$ 254 nm, 25 °C), t_R (major) = 8.23 min, t_R (minor) = 9.55 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.83 (d, J = 7.4

Hz, 1H), 7.35 – 7.22 (m, 1H), 7.14 (t, J = 7.6 Hz, 1H), 6.87 – 6.85 (m, 2H), 6.56 – 6.54 (m, 3H), 4.86 (t, J = 2.0 Hz, 1H), 4.27 (q, J = 7.1 Hz, 2H), 3.68 (s, 3H), 2.82 (s, 3H), 2.44 (d, J = 4.1 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H); ¹³**C NMR** (100 MHz, CDCl₃): δ (ppm) 170.89, 167.22, 158.94, 143.95, 130.02, 129.23, 126.10, 125.93, 125.37, 122.41, 112.78, 107.90, 82.67, 73.04, 63.55, 62.28, 55.08, 42.08, 26.12, 14.02; **HRMS** (ESI) for: C₂₂H₂₂NO₄ [M+H]⁺: calcd 364.1543, found 364.1551.

Ethyl (S)-3-((R)-1-(4-methoxyphenyl)prop-2-yn-1-yl)-1-methyl-2-oxoindoline-3-carboxylate ((S,R)-3k)



White solid, 50% yield, $[\alpha]_D^{23} = 0.997$ (c = 1.00 in CH₂Cl₂); 74% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 13.61 min, t_R (minor) = 23.42 min; ¹H **NMR** (400 MHz, CDCl₃): δ (ppm) 7.31 – 7.22 (m, 1H), 7.08 (m,

3H), 7.01 (t, J = 7.5 Hz, 1H), 6.69 – 6.62 (m, 3H), 4.80 (t, J = 2.1 Hz, 1H), 4.26 – 4.19 (m, 2H), 3.73 (d, J = 1.5 Hz, 3H), 3.03 (d, J = 1.6 Hz, 3H), 2.30 (d, J = 4.4 Hz, 1H), 1.22 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 171.20, 167.57,

159.11, 144.17, 130.46, 129.31, 126.28, 125.21, 125.12, 122.06, 112.97, 107.95, 81.00, 72.94, 63.40, 62.23, 55.15, 42.39, 26.21, 13.96; **HRMS** (ESI) for: $C_{22}H_{21}NO_4Na$ [M+Na]⁺: calcd 386.1363, found 386.1370.

Ethyl (R)-1-methyl-3-((R)-1-(naphthalen-2-yl)prop-2-yn-1-yl)-2-oxoindoline-3-carboxylate ((*R*,*R*)-3l)



White solid, 39% yield, $[\alpha]_D^{23} = 0.718$ (c = 1.00 in CH₂Cl₂); 88% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, λ = 254 nm, 25 °C), t_R (major) = 7.05 min, t_R (minor) = 9.29 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.91 (d, *J* = 7.4

Hz, 1H), 7.71 – 7.56 (m, 2H), 7.52 – 7.32 (m, 4H), 7.24 – 7.17 (m, 2H), 7.05 – 7.02 (m, 1H), 6.41 (d, J = 7.7 Hz, 1H), 5.10 – 5.06 (m, 1H), 4.30 (q, J = 7.1 Hz, 2H), 2.66 (s, 3H), 2.50 (d, J = 3.5 Hz, 1H), 1.28 (t, J = 7.8 Hz, 3H); ¹³**C NMR** (100 MHz, CDCl₃): δ (ppm) 170.80, 167.18, 143.89, 132.59, 132.57, 131.54, 129.31, 128.39, 127.91, 127.26, 126.83, 126.53, 125.98, 125.94, 125.74, 125.28, 122.47, 107.92, 82.40, 73.41, 63.54, 62.36, 42.87, 26.02, 14.02; **HRMS** (ESI) for: C₂₅H₂₂NO₃ [M+H]⁺: calcd 348.1594, found 348.1600.

Ethyl (S)-1-methyl-3-((R)-1-(naphthalen-2-yl)prop-2-yn-1-yl)-2-oxoindoline-3-carboxylate ((S,R)-3l)



White solid, 52% yield, $[\alpha]_D^{23} = 1.024$ (c = 1.00 in CH₂Cl₂); 96% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, λ = 254 nm, 25 °C), t_R (major) = 9.91 min, t_R (minor) = 19.58 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.81 – 7.58 (m, 4H), 7.49 – 7.38 (m, 2H), 7.34 – 7.19 (m, 2H),

7.12 – 6.97 (m, 2H), 6.58 (d, J = 7.8 Hz, 1H), 5.06 – 5.01 (m, 1H), 4.24 (q, J = 7.1 Hz, 2H), 2.99 (s, 3H), 2.36 (d, J = 3.8 Hz, 1H), 1.22 (t, J = 7.1 Hz, 3H); ¹³**C NMR** (100 MHz, CDCl₃): δ (ppm) 171.18, 167.55, 144.17, 132.75, 132.71, 131.82, 129.41, 128.81, 127.97, 127.41, 127.14, 127.06, 126.12, 125.96, 125.35, 125.01, 122.08, 108.01, 80.77, 73.32, 63.36, 62.34, 43.20, 26.22, 13.96; **HRMS** (ESI) for: C₂₅H₂₂NO₃ [M+H]⁺: calcd 348.1594, found 348.1600.

Ethyl (R)-3-((S)-1-(6-bromobenzo[d][1,3]dioxol-5-yl)prop-2-yn-1-yl)-1-methyl-2-oxoindoli ne-3-carboxylate ((*R*,*S*)-3m)



White solid, 37% yield, $[\alpha]_D^{23} = -6.717$ (c = 1.00 in CH₂Cl₂); 91% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (minor) = 6.68 min, t_R (major) = 8.26 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.67 (d, J = 7.5 Hz, 1H), 7.40 (t, J = 7.8 Hz, 1H), 7.15 (t, J = 7.6 Hz, 1H),

6.93 (d, J = 1.3 Hz, 1H), 6.77 (d, J = 7.8 Hz, 1H), 6.44 (d, J = 1.3 Hz, 1H), 5.90 – 5.82 (m, 2H), 5.43 (d, J = 3.8 Hz, 1H), 4.22 – 4.16 (m, 2H), 3.01 (s, 3H), 2.35 (d, J = 3.8 Hz, 1H), 4.22 – 4.16 (m, 2H), 3.01 (s, 3H), 2.35 (d, J = 3.8 Hz, 1H), 4.22 – 4.16 (m, 2H), 3.01 (s, 3H), 2.35 (d, J = 3.8 Hz, 1H), 4.22 – 4.16 (m, 2H), 3.01 (s, 3H), 2.35 (d, J = 3.8 Hz, 1H), 4.22 – 4.16 (m, 2H), 3.01 (s, 3H), 2.35 (d, J = 3.8 Hz, 1H), 4.22 – 4.16 (m, 2H), 3.01 (s, 3H), 2.35 (d, J = 3.8 Hz, 1H), 4.22 – 4.16 (m, 2H), 3.01 (s, 3H), 2.35 (d, J = 3.8 Hz, 1H), 4.22 – 4.16 (m, 2H), 3.01 (s, 3H), 3.01 (s,

3.7 Hz, 1H), 1.19 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 170.85, 167.22, 147.73, 146.86, 144.57, 129.84, 128.45, 125.75, 125.54, 122.74, 115.78, 112.42, 109.54, 108.15, 101.70, 81.99, 72.80, 62.35, 62.14, 40.34, 26.40, 13.90; HRMS (ESI) for: C₂₂H₁₉BrNO₅ [M+H]⁺: calcd 456.0441, found 456.0442.

Ethyl (S)-3-((S)-1-(6-bromobenzo[d][1,3]dioxol-5-yl)prop-2-yn-1-yl)-1-methyl-2-oxoindoli ne-3-carboxylate ((*S*,*S*)-3m)



White solid, 38% yield, $[\alpha]_D^{23} = 3.518$ (c = 1.00 in CH₂Cl₂); 85% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (minor) = 9.36 min, t_R (major) = 16.27 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.53 (d, J = 7.5 Hz, 1H), 7.27 – 7.20 (m, 1H), 7.09 (d, J = 1.3 Hz, 1H), 7.00

(t, J = 7.6 Hz, 1H), 6.75 (d, J = 1.3 Hz, 1H), 6.65 (d, J = 7.8 Hz, 1H), 5.96 – 5.87 (m, 2H), 5.39 (t, J = 2.0 Hz, 1H), 4.24 (q, J = 7.1 Hz, 2H), 3.17 (s, 3H), 2.36 (d, J = 4.0 Hz, 1H), 1.22 (t, J = 7.8 Hz, 3H); ¹³**C NMR** (100 MHz, CDCl₃): δ (ppm) 171.65, 167.68, 147.96, 147.42, 143.68, 129.69, 128.13, 125.72, 124.51, 122.13, 115.55, 112.20, 109.83, 107.88, 101.96, 80.90, 73.16, 62.55, 62.34, 40.65, 26.46, 13.99; **HRMS** (ESI) for: C₂₂H₁₉BrNO₅ [M+H]⁺: calcd 456.0441, found 456.0442.

Ethyl (R)-3-((S)-but-3-yn-2-yl)-1-methyl-2-oxoindoline-3-carboxylate ((R,S)-3n)



White solid, 43% yield, $[\alpha]_D^{23} = 0.708$ (c = 1.00 in CH₂Cl₂); 98% ee, determined by HPLC analysis (Chiralpak OJ column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 8.13 min, t_R (minor) = 9.06 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.58 (d, J = 7.5 Hz, 1H), 7.36 (t, J = 7.7 Hz, 1H), 7.11 (t, J = 7.6 Hz,1H), 6.86 (d, J = 7.8 Hz, 1H), 4.30 – 4.12 (m, 2H), 3.71 – 3.65 (m,

1H), 3.24 (s, 3H), 2.09 (d, J = 3.7 Hz, 1H), 1.22 (t, J = 7.1 Hz, 3H), 1.07 (d, J = 5.7 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 171.77, 167.62, 144.19, 129.23, 126.19, 124.79, 122.83, 108.06, 83.97, 70.75, 62.17, 61.71, 31.70, 26.45, 15.56, 13.93; HRMS (ESI) for: C₁₆H₁₈NO₃ [M+H]⁺: calcd 272.1281, found 272.1283.

Ethyl (S)-3-((S)-but-3-yn-2-yl)-1-methyl-2-oxoindoline-3-carboxylate ((S,S)-3n)



White solid, 56% yield, $[\alpha]_D^{23} = 0.351$ (c = 1.00 in CH₂Cl₂); 96% ee, determined by HPLC analysis (Chiralpak OJ column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (minor) = 10.04 min, t_R (major) = 11.31 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.38 – 7.32 (m, 2H), 7.09 (t, J = 7.6 Hz, 1H), 6.87 (d, J = 7.8 Hz, 1H), 4.20 (q, J = 7.1 Hz, 2H), 3.65 – 3.59 (m, 1H), 3.25 (s, 3H),

2.03 (d, J = 2.9 Hz, 1H), 1.22 – 1.19 (m, 6H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 171.99, 167.73, 144.50, 129.32, 125.76, 124.39, 122.57, 108.18, 82.99, 70.57, 62.09, 61.88, 31.62, 26.37, 15.82, 13.92; **HRMS** (ESI) for: C₁₆H₁₇NO₃Na [M+Na]⁺: calcd 294.1101, found 294.1105.

Ethyl (R)-1-methyl-2-oxo-3-((S)-5-phenylpent-1-yn-3-yl)indoline-3-carboxylate ((R,S)-30)



White solid, 39% yield, $[\alpha]_D^{23} = 0.906$ (c = 1.00 in CH₂Cl₂); 94% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (minor) = 6.61 min, t_R (major) = 7.22 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.57 (d, J = 7.5 Hz, 1H), 7.39 – 7.01 (m, 7H), 6.83 (d, J = 7.7 Hz, 1H), 4.27 – 4.10 (m, 2H),

3.66 – 3.52 (m, 1H), 3.21 (s, 3H), 2.95 – 2.88 (m, 1H), 2.67 – 2.60 (m, 1H), 2.17 (d, J = 4.0 Hz, 1H), 1.68 – 1.58 (m, 2H), 1.19 (t, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 171.71, 167.53, 144.06, 141.17, 129.22, 128.51, 128.31, 126.46, 125.93, 124.76, 122.85, 108.16, 82.39, 72.30, 62.23, 61.71, 37.31, 33.73, 31.09, 26.52, 13.91; **HRMS** (ESI) for: C₂₃H₂₄NO₃ [M+H]⁺: calcd 362.1751, found 362.1752.

Ethyl (S)-1-methyl-2-oxo-3-((S)-5-phenylpent-1-yn-3-yl)indoline-3-carboxylate ((S,S)-30)



White solid, 51% yield, $[\alpha]_D^{23} = 0.426$ (c = 1.00 in CH₂Cl₂); 94% ee, determined by HPLC analysis (Chiralpak AD column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (minor) = 6.83 min, t_R (major) = 7.31 min; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.41 – 6.99 (m, 8H), 6.84 (d, *J* = 7.8 Hz, 1H), 4.17 (q, *J* = 7.1 Hz, 2H), 3.52 – 3.40 (m, 1H), 3.23

(s, 3H), 2.98 – 2.91 (m, 1H), 2.69 – 2.61 (m, 1H), 2.13 (d, J = 3.9 Hz, 1H), 1.89 – 1.51 (m, 2H), 1.17 (t, J = 7.1 Hz, 3H); ¹³**C NMR** (100 MHz, CDCl₃): δ (ppm) 171.99, 167.71, 144.49, 140.98, 129.35, 128.51, 128.36, 126.01, 125.73, 124.40, 122.62, 108.20, 81.57, 72.02, 62.14, 61.74, 36.88, 33.73, 31.37, 26.41, 13.89; **HRMS** (ESI) for: C₂₃H₂₃NO₃Na [M+Na]⁺: calcd 384.1570, found 384.1575.

Ethyl (R)-3-((S)-1-cyclohexylprop-2-yn-1-yl)-1-methyl-2-oxoindoline-3-carboxylate ((*R*,*S*)-3p)



White solid, 33% yield, $[\alpha]_D^{23} = 0.983$ (c = 1.00 in CH₂Cl₂); 71% ee, determined by HPLC analysis (Chiralpak IC column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 8.90 min, t_R (minor) = 12.29 min; ¹H **NMR** (400 MHz, CDCl₃): δ (ppm) 7.64 (d, J = 7.5 Hz, 1H), 7.34 (t, J = 7.7 Hz, 1H), 7.09 (t, J = 7.6 Hz, 1H), 6.84 (d, J =

7.8 Hz, 1H), 4.21 – 4.15 (m, 2H), 3.57 – 3.55 (m, 1H), 3.24 (s, 3H), 2.15 (d, J = 2.2 Hz, 1H), 1.74 – 1.33 (m, 5H), 1.30 – 1.24 (m, 1H), 1.21 (t, J = 6.9 Hz, 3H), 1.17 – 1.08 (m, 2H), 1.06 – 0.90 (m, 3H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 171.77, 167.98, 143.79, 129.05, 127.49, 125.49, 122.69, 108.05, 82.09, 72.73, 62.25, 61.45, 43.22, 38.43, 32.68, 29.79, 26.56, 26.39, 26.07, 25.86, 13.88; **HRMS** (ESI) for: C₂₁H₂₆NO₃ [M+H]⁺: calcd 340.1907, found 340.1916.

Ethyl (S)-3-((S)-1-cyclohexylprop-2-yn-1-yl)-1-methyl-2-oxoindoline-3-carboxylate ((S,S)-3p)



White solid, 42% yield, $[\alpha]_D^{23} = 0.193$ (c = 1.00 in CH₂Cl₂); 58% ee, determined by HPLC analysis (Chiralpak IC column, hexane/i-PrOH, 70:30 v/v, flow rate 1 mL/min, $\lambda = 254$ nm, 25 °C), t_R (major) = 33.63 min, t_R (minor) = 59.70 min; ¹H **NMR** (400 MHz, CDCl₃): δ (ppm) 7.35 (t, J = 7.7 Hz, 1H), 7.29 – 7.24 (m, 1H), 7.09 (t, J = 7.6 Hz, 1H), 6.86 (d, J = 7.8

Hz, 1H), 4.22 - 4.15 (m, 2H), 3.52 (t, J = 2.9 Hz, 1H), 3.23 (s, 3H), 2.13 (d, J = 3.5 Hz, 1H), 1.74 - 1.45 (m, 5H), 1.33 - 1.25 (m, 3H), 1.21 (t, J = 7.1 Hz, 3H), 1.15 - 0.96 (m, 3H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 172.35, 168.32, 144.28, 129.28, 125.84, 124.39, 122.57, 108.18, 80.87, 72.65, 62.20, 61.29, 43.32, 37.66, 32.92, 30.13, 26.43, 26.40, 26.00, 25.78, 13.85; **HRMS** (ESI) for: $C_{21}H_{25}NO_3Na$ [M+Na]⁺: calcd 362.1727, found 362.1732.

Ethyl (S)-6-bromo-3-((R)-(1-((2S,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)-1H-1,2,3-triazol-4-yl)(phenyl)methyl)-1-m ethyl-2-oxoindoline-3-carboxylate (4)



White solid, 90% yield, $[\alpha]_D^{23} = -1.290$ (c = 1.00 in CH₂Cl₂); >95:5 d.r.; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 9.47 (s, 1H), 7.57 (d, J = 8.1 Hz, 1H), 7.44 (s, 1H), 7.39 (s, 1H), 7.22 - 7.00 (m, 4H), 6.95 (d, J = 7.6 Hz, 2H), 6.72 (s, 1H), 6.22 (t, J = 6.5 Hz, 1H), 5.37 - 5.34 (m, 2H), 4.44 - 4.33 (m, 1H), 4.25 - 4.06 (m, 2H), 3.98 (d, J = 12.3 Hz, 1H), 3.79 - 3.68 (m, 1H), 3.59 (s, 1H), 2.91 (t, J = 6.9 Hz, 2H), 2.79 (s,

3H), 1.88 (s, 3H), 1.13 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 171.72, 167.31, 163.90, 150.46, 147.28, 145.43, 137.80, 136.15, 129.47, 129.14, 127.75, 125.42, 125.01, 123.56, 122.69, 111.27, 111.17, 88.51, 85.15, 63.97, 62.31, 61.50, 59.11, 48.15, 37.39, 26.25, 13.80, 12.37; **HRMS** (ESI) for: C₃₁H₃₂BrN₆O₇ [M+H]⁺: calcd 679.1510, found 679.1516.

5. X-ray structure of (*S*,*R*)-3i and (*R*,*S*)-3m



References

- (a) J. Gao, J. R. Chen, S. W. Duan, T. R. Li, L. Q. Lu and W. J. Xiao, Asian J. Org. Chem., 2014, 3, 530-535; (b) J. G. Wang, S. Osman, X. J. Lu, J. Y. Chen and X. D. Xia, *Heterocycl. Commun.*, 2020, 26, 168-175.
- (a) G. Hattori, K. Sakata, H. Matsuzawa, Y. Tanabe, Y. Miyake and Y. Nishibayashi, J. Am. Chem. Soc., 2010, 132, 10592-10608; (b) D. Y. Zhang, L. Shao, J. Xu and X. P. Hu, ACS Catal., 2015, 5, 5026-5030; (c) K. Zhang, L. Q. Lu, S. Yao, J. R. Chen, D. Q. Shi and W. J. Xiao, J. Am. Chem. Soc., 2017, 139, 12847-12854.



6. Copies of ¹H and ¹³C NMR Spectra
































































7. Copies of HPLC Chromatography





-20					12-	17.517		
8	3.00 8.75 10.00	11.25 12	.50 13.75 Time (m	15.00 in]	16.25 17.50	18.75	20.00	
Integr	Integration Results							
No.	Peak Name	Retention Time	Area	Height	Relative Area	Relative Height	Amount	
		min	mAU*min	mAU	%	%	n.a.	
1		8.900	36.894	152.968	97.52	98.77	n.a.	
2		17.517	0.940	1.907	2.48	1.23	n.a.	
Total:	Total: 37.834 154.875 100.00 100.00							















274.878

Total:

193.816

100.00

100.00

S54



















megi									
No.	Peak Name	Retention Time	Area	Height	Relative Area	Relative Height	Amount		
		min	mAU*min	mAU	%	%	n.a.		
1		7.137	92.688	493.801	96.31	98.23	n.a.		
2		14.163	3.555	8.877	3.69	1.77	n.a.		
Total:			96.244	502.677	100.00	100.00			











50 -

(S,R)-3g



Integration Results								
No.	Peak Name	Retention Time	Area	Height	Relative Area	Relative Height	Amount	
		min	mAU*min	mAU	%	%	n.a.	
1		4.750	20.251	112.508	52.86	49.42	n.a.	
2		5.407	18.058	115.137	47.14	50.58	n.a.	
Total:			38.309	227.645	100.00	100.00		







1.259

28.770

4.723

160.019

4.37

100.00

2.95

100.00

n.a.

9.537

fotal:





140.	i car manie	Retenuon nine	Aica	rieigin	Relative Area	Relative Height	Amount
		min	mAU*min	mAU	%	%	n.a.
1		11.517	20.176	59.339	50.15	52.93	n.a.
2		12.567	20.053	52.768	49.85	47.07	n.a.
Total:			40.229	112.107	100.00	100.00	











INO.	Peak Name	Retention Time	Area	Height	Relative Area	Relative Height	Amount
		min	mAU*min	mAU	%	%	n.a.
1		13.310	12.441	32.976	50.51	65.44	n.a.
2		23.650	12.188	17.418	49.49	34.56	n.a.
Total:			24.629	50.393	100.00	100.00	



119.732

919.474

172.390

1987.417

13.02

100.00

8.67

100.00

n.a.

23.420

2

Total:

C	7	n
С	1	υ










No.	Peak Name	Retention Time	Area	Height	Relative Area	Relative Height	Amount		
		min	mAU*min	mAU	%	%	n.a.		
1		9.463	51.315	189.312	49.81	65.68	n.a.		
2		16.373	51.706	98.934	50.19	34.32	n.a.		
Total:			103.020	288.245	100.00	100.00			





integration results								
No.	Peak Name	Retention Time	Area	Height	Relative Area	Relative Height	Amount	
		min	mAU*min	mAU	%	%	n.a.	
1		8.083	44.203	122.492	49.66	57.24	n.a.	
2		8.980	44.801	91.504	50.34	42.76	n.a.	
Total:			89.004	213.997	100.00	100.00		



57.259

2

Total:

1.19

100.00

175.084

1.23

100.00

n.a.



No.	Peak Name	Retention Time	Area	Height	Relative Area	Relative Height	Amount
		min	mAU*min	mAU	%	%	n.a.
1		9.957	90.080	220.536	49.75	64.07	n.a.
2		11.287	90.986	123.667	50.25	35.93	n.a.
Total:			181.066	344.202	100.00	100.00	









